SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Tuesday reported a loss of $62.1 million in its third quarter.
The San Diego-based company said it had a loss of 50 cents per share.
The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 58 cents per share.
The drugmaker posted revenue of $58.3 million in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $57.9 million.
Acadia shares have dropped 27 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $21.88, a fall of 33 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ACAD at https://www.zacks.com/ap/ACAD